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a b s t r a c t
The success of levodopa and other classes of drugs have meant that most people with Parkinson's disease
enjoy a good quality of life for many years. However, despite the availability of several drugs and for-
mulations that can be used as monotherapy and in combination, there are a number of disease features
that the current therapies are unable to address. The disease continues to progress despite treatment,
patients suffer from a myriad of motor and non-motor symptoms, and a neuroprotective therapy is
urgently required. To move forward with medical and surgical management, it is important to consider
new insights that recent research offers and in this review we examine how a better understanding of
the disease pathology and progression might improve and enrich our daily clinical practice. It is also
timely to consider the service provision changes that will increasingly be needed to effectively manage
the needs of the aging population.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Parkinson's disease (PD) is among the most common neurode-
generative disorders, the prevalence of which increases with
advancing age. With today's rapidly ageing society it is predicted
that the PD patient population will at least double by 2030 [1], and
the associated increase in medical costs will be considerable [2].
The success of levodopa and other drug classes hasmeant that most
patients can enjoy a good quality of life for many years [3,4].
However, despite the availability of several drugs and formulations
that can be used as monotherapy and in combination, there are a
number of disease features that the current therapies are unable to
address.
Key medical unmet needs in PD include the need for better
animal models replicating the parkinsonian process, slowing of
disease progression/neuroprotection, improved biomarkers (im-
aging, genetic, clinical or other modality), improved 24-h control of
motor ﬂuctuations in moderate to advanced disease and more
effective treatment of non-motor symptoms (NMS). Nocturnal
symptoms as well as early morning ﬂuctuations (motor and NMS)
remain neglected [5]. To move forward with medical management,
it is important to consider new insights that recent research offers
and in this review we examine how a better understanding of the
disease pathology and progression might inform our daily clinical
practice.
2. Research challenge
2.1. Animal models of disease pathology
As past research focused on dopaminergic replacement therapy
for motor symptoms, the traditional dopamine lesion models (i.e.
the 6-hydroxydopamine rat model and MPTP-treated monkey
models) formed an important basis for drug development. Indeed,
these models were generally helpful in predicting symptomatic
motor responses to dopaminergic therapy [6]. However, these have
been of limited value in predicting the results of potential neuro-
protective therapies, and this is fundamentally because they do not
reﬂect the true complex etiopathogenesis of PD, neither do they
* Corresponding author.
E-mail address: rbh@chulapd.org (R. Bhidayasiri).
Contents lists available at ScienceDirect
Parkinsonism and Related Disorders
journal homepage: www.elsevier .com/locate/parkreldis
http://dx.doi.org/10.1016/j.parkreldis.2016.11.018
1353-8020/© 2016 Elsevier Ltd. All rights reserved.
Parkinsonism and Related Disorders xxx (2016) 1e7
Please cite this article in press as: K.R. Chaudhuri, et al., Unmet needs in Parkinson's disease: New horizons in a changing landscape,
Parkinsonism and Related Disorders (2016), http://dx.doi.org/10.1016/j.parkreldis.2016.11.018
show progression or Lewy body formation [7]. Additional preclin-
ical models have been developed and these are summarized in
Table 1. However, no current preclinical model is able to adequately
mirror the tremendous complexity of PD itself.
Indeed, there have been signiﬁcant advances in understanding
the pathophysiology of PD over the past decades and it is now
better understood that the disease follows a deﬁned clinical
pattern, with a range of NMS deﬁning the pre-motor phase [8]. In
the prodromal stage, the most common NMS manifestations are
olfactory impairment and raid eye movement behavior disorder
while other features such as constipation, somnolence, apathy, fa-
tigue may also be present [9]. The development of many of these
symptoms is consistent with the Braak pathology staging in which
Lewy bodies ﬁrst develop in the dorsal motor nucleus of the vagus
nerve, the olfactory bulb, enteric nervous system and the sub-
mandibular gland, and then later spread to the substantia nigra,
areas of the midbrain and basal forebrain, and ﬁnally reach areas of
the neocortex [10]. Indeed, recent research has implicated the
vagus nerve and the gut-brain axis as a potential generator of the
pathological process in PD [11]. Added to this complexity, many
cellular mechanisms such as protein degradation, oxidative stress,
mitochondrial defects, proteolytic stress, neuroinﬂammation, an
impaired ubiquitin protesomal system and autophagy have been
suggested to play a role in PD [12]. None of the currently used
models of disease, and certainly none of the toxin-induced lesion
models, reliably reﬂect this complex neuropathology e represent-
ing a key unmet scientiﬁc need in PD [13].
2.2. Biomarkers of disease progression
New MDS diagnostic criteria for PD have moved away from an
approach wholly based on motor symptoms to a combination of
central core motor and non-motor features [14]. In this respect,
clinical, genetic and imaging biomarkers are emerging as strong
predictors of diagnosis and progression e although much work still
needs to be done to exactly deﬁne the speciﬁcity and sensitivity of
such tests [15]. The availability of a biomarker battery or package
would enable accurate and early diagnosis based on objective ev-
idence allowing for improved individualized therapy as well as for
monitoring progression. Indeed, a good biomarker or biomarkers
could be used to conﬁrm diagnosis, assess disease progression, and
even identify individuals who are in the prodromal stages of the
disease [16e18].
Biomarkers can be categorized as ‘trait’ (biomarkers which are
stable over time), ‘state’ (biomarkers which change with disease
progression or treatment), and ‘pharmacodynamic’ (sometimes
referred to as mechanism of action markers). Several potential
biomarkers have been pursued, ranging from neuroimaging to
possible markers in the blood [19], CSF [20], and even the colon
[21]. Speciﬁcally, molecular pathways related to a-synuclein, tau
and b-amyloid peptides have received considerable attention. Such
advances have been extensively reviewed elsewhere [22e25].
Although there are several promising candidates under evaluation,
there is increasing consensus that no single candidate will provide
full utility in isolation. A combinatorial approach, using a variety of
approaches that take into account the multifactorial pathogenesis
of PD will likely be necessary. Recent evidence also suggests that
sleep and imaging measures, and to some extent NMS (assessed
using appropriate NMS scales) may be more helpful than currently
available CSF biomarkers and cognitive scales in quantifying pro-
gression [15].
2.3. Understanding PD phenotype and disease progression
It is well established that rates of disease progression in PD can
be variable, and the motor subtype divisions of ‘tremor dominant’
versus ‘postural instability/gait difﬁculty’ (PIGD) parkinsonism
have been broadly accepted and used in a variety of clinical studies
[26e29]. Although deﬁnitions and methodologies have varied,
studies generally have reported a worse prognosis in terms of
disability, quality of life, disease progression and risk of dementia
for patients with the PIGD phenotype as compared with the tremor
dominant phenotype [30e33]. However, accumulating evidence is
bringing the longitudinal stability of these phenotypes into ques-
tion [34]. The Parkinson's Progression Markers Initiative (PPMI) has
published one-year analysis data from patients who were un-
treated at the time of enrollment. The study found substantial
instability of motor subtype; almost a third (29%) of patients orig-
inally classiﬁed as having PIGD dominant disease shifted to a
tremor dominant phenotype during the ﬁrst year of diagnosed
disease [35]. This instability of motor phenotypes, and the recog-
nition that PD subtypes are largely characterized by the severity of
non-dopaminergic features has led to evaluation of non-motor
symptoms as an alternative scheme.
According to the concept of NMS subtyping, the predominant
NMS symptoms experienced will depend on which non-
dopaminergic nuclei (in the limbic and brainstem areas) are most
affected by the underlying disease neuropathology and spread. In
one recent proposal, Sauerbier et al. suggested at least seven
distinct NMS dominant subtypes of PD: Cognitive dominant, apathy
dominant, depression/anxiety dominant, sleep dominant, pain
dominant, fatigue dominant and autonomic dominant [8]. Within
this scheme, sleep-dominant and autonomic-dominant subtypes
are grouped into a ‘brainstem phenotype,’ where the underlying
pathology is thought to involve the brainstem and olfactory route.
Likewise, the cognitive dominant subtype is thought to reﬂect late-
onset disease where cortical pathology predominates and the
depression, fatigue and pain dominant subtypes are grouped under
a ‘limbic phenotype’ where the olfactory route predominates [8].
The stability of non-motor subtypes has not been studied and it is
probable that non-motor subtypes will also change throughout the
disease course. Nevertheless, this form of NMS PD subtyping allows
for future PD research to be more focused, by utilizing a subset of
speciﬁc patients and working to improve their quality of life.
3. Treatment challenges
3.1. Neuroprotection
The prime unmet clinical need in PD is a ‘neuroprotective’ and/
or ‘disease-modifying’ treatment that can halt or at least slow the
progression of this progressive disease. While there have been
many promising candidate agents in preclinical studies, no drug or
treatment strategy has proven to be neuroprotective or disease-
modifying in PD. Some of the key barriers to development of
such an agent have already been described above. The lack of a
robust model (or models) of disease with a prolonged prodromal
period, severely impairs our ability to screen and test new products.
Without validated biomarkers of disease, it is virtually impossible
to prove an effect on the underlying disease progression. Recent
experience with the rasagiline ADAGIO trial [36] showed us that it
can be very hard to interpret clinical data, no matter how sophis-
ticated the trial design is [37,38], and the availability of a biomarker
is now considered a pre-requisite for the development of new
disease-modifying treatment strategies for PD [39,40]. Moreover,
since patients already have undergone signiﬁcant neuro-
degeneration before they develop overt motor symptoms, treat-
ment at diagnosis may already be too late for a neuroprotective
agent. The only way would be to accurately identify pre-motor
patients, and this would require a reliable biomarker [41].
K.R. Chaudhuri et al. / Parkinsonism and Related Disorders xxx (2016) 1e72
Please cite this article in press as: K.R. Chaudhuri, et al., Unmet needs in Parkinson's disease: New horizons in a changing landscape,
Parkinsonism and Related Disorders (2016), http://dx.doi.org/10.1016/j.parkreldis.2016.11.018
Moreover, it is only possible to demonstrate that drug slows the
rate of progression, when one has an understanding of the
benchmark rate. Finally, given the heterogeneity of disease, it is
entirely likely that not all medications will be suitable for all pa-
tients and an understanding of disease types will be essential.
3.2. Management of motor complications
In the absence of a neuroprotective agent, we must rely on the
effective management of symptoms (motor and non-motor). At
present, levodopa remains unchallenged as the most efﬁcacious
and best tolerated antiparkinsonian drug, albeit one that is often
limited by the development of response ﬂuctuations and dyskinesia
[42,43]. Motor ﬂuctuations are almost invariably associated with
often disabling non motor ﬂuctuations [44]. Patient surveys
consistently highlight the negative impact that being ‘OFF’ has on
the patient [45,46], and other studies show the signiﬁcant impact of
motor ﬂuctuations on patient quality of life [3,47]. In particular, the
early morning OFF state is associated with signiﬁcant and dis-
tressing NMS as shown in a recent multicenter survey [48] and
management of this common problem remains a key unmet need.
Recent studies using apomorphine injections for ﬁrst dose of the
day or for dose failures in PD are therefore timely [49].
We now better understand that the dose and pulsatile phar-
macokinetics of levodopa are closely associated with the develop-
ment of motor complications [50e52] and, together with the
development of a broad armamentarium of adjunctive therapies
(i.e. dopamine agonists, MAO-B inhibitors, COMT inhibitors and
amantadine), we are now better equipped to design better treat-
ment strategies for our patients with motor ﬂuctuations. However,
it is also clear that, despite all these advances, current standards of
therapy do not completely abolish motor ﬂuctuations. This is one
area where a greater understanding of the full impact of disease e
beyond the central nervous system e may help. For example,
widespread involvement of the GI system is common in PD, with
alpha synuclein and Lewy bodies demonstrated throughout the
enteric nervous system, including within myenteric neurons [53]
(Table 2). Indeed, it is now estimated that >70% PD patients have
GI disorders, including gastric dysmotility (gastroparesis) and
bacterial overgrowth [54]. Very importantly, these GI problems can
occur early on in the course of PD, and should no longer be
considered a feature of advanced disease [54,55]. Since levodopa
andmany other orally administered PD drugs are absorbed in small
intestine, it is thought that these problems might be a key
contributor to motor ﬂuctuations in some patients [54]. If the drug
is not absorbed, it cannot be expected to exert its therapeutic
action.
The relevance of drug absorption cannot be underestimated,
and has led to a reappraisal of howwe viewOFF episodes. Whereas,
we once very much focused on ‘end-of-dose wearing-off’, we now
increasingly consider the time taken to ON, which is related to drug
absorption and has been reported to be more than twice the
duration of wearing-off [56]. Nocturnal hypokinesia and early
morning off is often the longest OFF period in the daily treatment
cycle [5,57], and delays to ON time and dose failures have been
reported to account for >60% of daily OFF time [58]. As such, this
provides a rationale for using non-oral therapies such as apomor-
phine injections or infusion which do not rely on GI absorption to
manage motor ﬂuctuations in patients where oral treatments do
not provide sufﬁcient control. Signiﬁcant advances in continuous
non-oral levodopa delivery are also being made at an ever
increasing rate [59].
3.3. Management of non-motor complications
As discussed above, NMS are now considered a key component
of PD that are explained by the widespread pathology of the dis-
ease, and which may represent a clinical biomarker of its premotor
phase [60]. The burden of non-motor symptoms can deﬁne a pa-
tient's health-related quality of life [61], and is a major contributor
to increased healthcare costs [62]. However, clinicians often regard
the management of NMS as being secondary to motor symptom
control. This may, in part, be because clinicians do not feel as able to
deal with NMS as they do with motor symptoms. Although some
evidence supports the efﬁcacy of certain treatments for depression,
dementia, psychosis, constipation, orthostatic hypotension and
sialorrhea, there is insufﬁcient evidence for efﬁcacious treatments
for other important non-motor symptoms that certainly contribute
to poor quality of life, such as neurogenic bladder disturbance,
erectile dysfunction, fatigue, insomnia, apathy, anxiety and exces-
sive daytime sleepiness [60,63]. The emergence of recent controlled
trials concentrated on key non-motor issues such as Parkinson
associated pain [64] or sleep [65] is highly encouraging. Never-
theless, the broad spectrum of NMS in PD clearly highlight the need
for developing non-dopaminergic therapies that target the non-
dopaminergic degeneration in PD.
It is also important to note that some NMS are dopa responsive.
Levodopa response ﬂuctuations are not limited to motor symp-
toms, and most patients with motor ﬂuctuations also experience
NMS ﬂuctuations (NMS which worsen in OFF episodes) [66].
Recently, the EuroInf study clearly demonstrated that improve-
ments in dopaminergic responsive NMS (with levodopa and
apomorphine infusion) lead to robust improvements in quality of
life [67].
Table 1
Examples of current preclinical models for Parkinson's disease.
 Pharmacologic models
◦ Reserpine treated rodents
◦ Haloperidol treated rodents
 Neurotoxin and dopamine depletion based
◦ MPTP lesioned monkeys
◦ MPTP treated mice
◦ 6-OHDA lesioned rats (full and partial lesions)
 Pesticide-induced models
◦ Rotenone rodent model
◦ Paraquat and Maneb models
 Proteasomal inhibitor models
 Glial activation models
 Synuclein deposition based
◦ Transgenics
◦ Viral vectors
◦ Prion like propagation based
 Genetic model system based
◦ PINK1
◦ Parkin
◦ DJ1
◦ LRRK2
 Induced pluripotent cells
 Minipig models
Table 2
GI abnormalities prevalent in PD which may hamper oral drug absorption.
 Dysphagia
 Drooling
 Gastritis/H Pyori related
 Peptic ulcer/H Pylori
 Delayed Gastric emptying
 Small intestinal bacterial overgrowth (SIBO)
 Intestinal microbiota alteration
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3.4. Multidisciplinary service provision
To manage the complex needs of people with PD, it is increas-
ingly accepted that a multidisciplinary team (MDT) approach
should be developed to provide professional care in all motor and
non-motor aspects of PD throughout the course of the disease.
Healthcare providers are tasked not only to care for the patients but
also to offer assistance to their caregivers who play a vital role along
the illness trajectory. The MDT approach uses experts in PD from
different health care professions as needed. Members can include a
neurologist, a specialist Parkinson's nurse, a speech and language
therapist, a physiotherapist, a social worker, a psychiatrist, an
occupational therapist, a sexologist, and a dietician [68,69]. There
are different models of multidisciplinary teams: inpatient facility,
community rehabilitation facility, and synchronized multi-
disciplinary treatment in the community.
However, despite this understanding, national and international
surveys constantly identify problems with service implementation
[70e72]. One way to tackle this is to provide good evidence to
payers and service providers that the approach provides opportu-
nities for efﬁciencies. From the nursing perspective, there is ample
evidence that Parkinson's nurses, improve patients sense of well-
being, save money and improve care [73,74]. Parkinson's nurses
can provide a range invaluable services, from nurse prescribing, to
support of infusion therapies (levodopa and apomorphine), timely
referral to other services, not to mention patient and caregiver
education and emotional support [69]. From the perspective of the
allied therapy services, one of the main barriers has been to
demonstrate consistent efﬁcacy and cost beneﬁts [75]. While most
physiotherapy trials have shown short-term beneﬁts, most of the
observed differences between treatments have been small and the
studies have not been of high quality [76]. Nevertheless, systematic
reviews have found that physiotherapy interventions such as bal-
ance training combined with muscle strengthening, range of
movement andwalking training exercise, are effective in improving
balance in patients with Parkinson's disease and more effective
than balance exercises alone [77]. Complementary physical thera-
pies such as dancing, hydrotherapy and robotic gait training also
appear to be of therapeutic beneﬁt, increasing mobility and quality
of life in some people living with PD [78].
In terms of randomized controlled trials, the evidence base is
relatively small. Sturkenboom et al. conducted a randomized
controlled trial to evaluate the efﬁcacy of occupational therapy for
PD. In this study, home-based, individualized occupational therapy
led to an improvement in self-perceived performance in daily ac-
tivities in PD patients vs. control therapy [79]. More recently,
Monticone et al. reported a randomized controlled trial that
demonstrated a 25-point difference in MDS-UPDRS scores as well
as quality of life in favor of inpatient multidisciplinary rehabilita-
tion versus nursing care plus ‘standard’ physiotherapy (both groups
received the same duration of PT intervention) [80]. The question
remains which types of physical and occupational therapies pro-
vide the most beneﬁt, and how the cost of these interventions
balance against the costs of hospitalization and institutionalization.
This area of research deserves urgent attention.
3.5. Nursing home and end of life/palliative
In the ﬁnal stages of PD, it is now vital to consider that our
patients are now living longer with their disease and co-
morbidities. A growing body of evidence highlights a high burden
of difﬁcult-to-manage and highly debilitating non-motor symp-
toms (e.g. constipation, loss of bladder control, swallowing difﬁ-
culties, drooling, breathlessness, sleep problems and pain) [81,82],
signiﬁcant caregiver distress [83,84], and a high utilization of
medical services especially in the last year of life [85]. At this stage,
many patients move into nursing homes for their care, where the
majority of patients require support in performing activities of daily
living [86]. However, neurologists and PD nurses often lose track of
these patients and continuity of medical care can be difﬁcult for
these patients to access. In the US, one study of large Medicare
patients found that only a third (33%) of nursing home residents
with PD had outpatient neurologist care [85]. In a qualitative study
conducted in the Netherlands, patients reported a similar lack of
access, as well as a lack of emotional support and insufﬁcient staff
knowledge on PD-related issues (e.g. motor ﬂuctuations and the
need for adherence to medication timing) [87].
The lack of understanding of PD-related issues is also of key
concern when considering perioperative periods. People with
advanced PD often have a wide range of comorbidities and surgery
(particularly urological, ophthalmological and orthopedic proced-
ures) is common. Retrospective database studies have shown that
compared with age-matched controls, PD patients undergoing
surgery have longer hospital stays, more perioperative complica-
tions and higher in-hospital mortality [88e90]. This is because,
when hospitalized, patients with PD face some unique challenges
related to medication management, mental status changes, in-
fections, and emergence of psychiatric symptoms, and there is a
lack of awareness of simple solutions such as parenteral adminis-
tration of dopaminergic medication during long surgeries [91]. It is
therefore very important to recognize problems that may arise
upon hospitalization of a patient with PD and provide education to
health care professionals involved in the inpatient care of patients
with PD.
In the very end stages, the complexity of patient needs may
require specialist palliative care involvement that aims to deliver
physical, psychological, emotional and spiritual care for patients
and their caregivers. However, current medical systems have yet to
adequately respond to this need through the provision of palliative
care services to both PD patients and to affected families [92, 93].
For example, most people prefer to receive end-of-life care in
familiar surroundings rather than in hospital, and hospitals are
rarely set up to provide such services. Nevertheless, an interna-
tional survey of 11 countries found that a substantial proportion (up
to 75% in some countries) of PD deaths occurred in the hospital
setting [94]. A key barrier to the development of palliative care
pathways is the lack of evidence-based knowledge on how to build
a service that integrates neurological and palliative care [95, 96].
Uncertainty about the timing of palliative care means that often it is
not considered until a patient reaches crisis point, despite the
recognized need for early planning due to increased prevalence of
dementia [97]. More work also is needed to prevent inappropriate
hospital transfers near death e for example by providing training
and education regarding the needs of people living with very
advanced PD.
4. Summary and conclusions
In recent years, there has been tremendous progress in our
understanding of the underlying pathology of PD, together with an
increasing recognition that PD is more than a motor disorder
caused by dopamine degeneration. However, as might be expected,
there has been a time lag in drug development with few novel
therapies coming tomarket in recent years [98, 99]. For PD research
to move forward, we need to consider the impact of the numerous
recent insights on the development of new drugs and tailored
strategies. For many years, our focus has been on developing new
oral medications, but it is increasingly apparent that problems with
the GI system appear early in PD and can affect how oral medica-
tions are absorbed. This supports the recent surge in interest in
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non-oral therapies which bypass the GI system.
It also is timely to consider the projected increases in PD prev-
alence. Service provision plans for our aging population should
consider how a multidisciplinary team can increase efﬁciencies,
and treatment plans should consider the full patient journey e
from early diagnosis through to end of life care.
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